Mylan Pharmaceuticals’ EpiPen Auto-Injectors are currently in shortage, the FDA announced on May 9th. According to the FDA’s website, the shortage isrelated to manufacturing delays, but says the product is still currently available.
On May 7th, the organization known as Food Allergy Research & Education (FARE), called upon the FDA to investigate the EpiPen shortage. According to FARE’s website, it received reports of patients with food allergies having the inability to obtain prescriptions for epinephrine auto-injectors.
FARE developed a survey to determine the scope of the problem. The survey results said more than 400 people in 45 states have indicated that they have experienced difficulties filling or refilling epinephrine prescriptions at their local pharmacies.
In a statement on the FDA’s Facebook page, it said the organization is “committed to working closely with the epinephrine manufacturer to resolve all shortages as quickly as possible.”
How long will the EpiPen Shortage last?
The FDA said the epinephrine supply shortage is expected to be short-term. The organization will continue to update its Drug Shortages website, as more information on the issue becomes available. FDA officials say drug shortages are a top priority for them, as they pose a significant public health issue in the U.S.
Epinephrine is the first line of treatment, for the serious and potentially life-threatening allergic reaction associated with severe food allergies, known as anaphylaxis.
Kaleo’s Auvi-Q injector, an alternative to the EpiPen, is readily available and not currently in shortage, says the FDA’s website.
For more information on this issue, and for updated shortage information, you can visit the FDA’s website.
Consumers can also call Mylan Pharmaceuticals’ customer relations line at 800-796-9526.
Copy courtesy RetailMeNot RX saver*